Abstract
InthisissueoftheJournalofClinicalOncology,Rajkumaretal report on the results of a randomized phase III clinical trial of thalidomide plus dexamethasone compared to high-dose dexamethasone alone in newly diagnosed multiple myeloma. 1 In this study, coordinated by the Eastern Cooperative Oncology Group, 207 patients were randomly assigned to either thalidomide plus dexamethasoneorhigh-dosedexamethasonealone.Responserate, the primary end point, was significantly higher with thalidomide plus dexamethasone than single-agent high-dose dexamethasone (63% v 41%, respectively, P .002); however, this benefit was associated with important toxicities, including deep vein thrombosis (DVT) and treatment-related mortality, which were 5% and 4%, respectively. 1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
